Stage III Non-Small Cell Lung Cancer
Key Points
Key Points
- Stage III non-small cell lung cancer (NSCLC) represents one of the most heterogenous subgroups of lung cancer. Consequently, it is also the subgroup in which choice and sequence of multimodality treatment varies significantly among clinicians, with variations being observed across and within institutes.
- This guideline reviews the published evidence addressing diagnosis and management of stage III NSCLC and provides evidence-based guidance on the common clinical dilemmas that clinicians may have while evaluating a patient with suspected or known stage III NSCLC.
- Three randomized control trials (RCTs) were published in 2022 and 2023 and prompted an amendment to the 2021 guideline.
Diagnosis
...gnosis
...uation and Staging...
...n 1.1For patients with suspected s...
...ndation 1.2Following evaluation with CT scan as pe...
...ndation 1.3For patients with suspected stage I...
...commendation 1.4For patients who requi...
...n 1.5For patients who require pathologic assessmen...
...n 1.6For patients who have suspected or con...
...Practice PointBiopsy should generally be pe...
Treatment
...atment...
Surgery
...2.1For patients with stage IIIA (N2) NSCLC, i...
...tion 2.2(Update): Patients with stage...
...od Practice Point...
...age III NSCLC generally should not be exc...
...nce of oncogenic driver alterations, available th...
...and providers should consider enrollme...
...juvant Therapy...
...mmendation 3.1Patients who are planned for a...
...ndation 3.2(Update): Patients with stag...
...3.3For patients with resectable superior...
...djuvant Therapy...
...ation 4.1Patients with resected stage...
...ion 4.2(Update): Patients with resected stage II...
...commendation 4.3For patients with...
...ctable Disease...
...ndation 5.1Patients with stage III...
...n 5.2Concurrent chemotherapy delivered with rad...
...endation 5.3Patients with stage III NSCLC...
...mendation 5.4Patients with stage III NSCLC rec...
...ndation 5.5Doses higher than 60 Gy and up to 70...
...mmendation 5.6Patients with stage III NSCLC...
...ndation 5.7Patients with stage III NSCLC receiving...
...ure 1. Evaluation and Staging in S...
...Management of Stage III NSCLCArrows with d...